Comparison
Abacavir Hypersensitivity C5768819 vs 3 4 Metacarpal Synostosis C5558402
Clinical comparison between Abacavir Hypersensitivity and 3 4 Metacarpal Synostosis for differential diagnosis and treatment planning.
Abacavir Hypersensitivity C5768819
A potentially serious immune reaction to the HIV drug abacavir. Genetic testing is required before starting treatment to identify those at risk of this reaction.
3 4 Metacarpal Synostosis C5558402
Two hand bones (metacarpals) are fused together from birth. May reduce grip strength and affect hand appearance. Management is personalized based on severity.
6 comparison axes
Onset
Abacavir Hypersensitivity C5768819
Variable
3 4 Metacarpal Synostosis C5558402
0-0
Onset patterns differ
Severity
Abacavir Hypersensitivity C5768819
severe
3 4 Metacarpal Synostosis C5558402
mild
Different severity levels
Chronic
Abacavir Hypersensitivity C5768819
Acute
3 4 Metacarpal Synostosis C5558402
Chronic
Differing course
Communicable
Abacavir Hypersensitivity C5768819
No
3 4 Metacarpal Synostosis C5558402
No
Different transmission
Body System
Abacavir Hypersensitivity C5768819
immunologic
3 4 Metacarpal Synostosis C5558402
musculoskeletal
Same/different system
Category
Abacavir Hypersensitivity C5768819
immunologic
3 4 Metacarpal Synostosis C5558402
other
Different category
Bottom line
abacavir-hypersensitivity-C5768819 and 3-4-metacarpal-synostosis-C5558402 differ in severity, chronicity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | Abacavir Hypersensitivity C5768819 | 3 4 Metacarpal Synostosis C5558402 | Discriminating power |
|---|---|---|---|
| Timing of onset | Variable timing after abacavir exposure; not congenital | Present from birth | High |
| Systemic features | May involve fever, rash, or multi-organ symptoms; exact pattern varies | Localized hand difference without systemic illness | High |
| Hand function | Not a primary hand-bone abnormality | Possible reduced grip and altered hand appearance | Moderate |
When to favor each condition
Choose Abacavir Hypersensitivity C5768819 when
Symptoms begin after starting abacavir
Temporal drug exposure supports hypersensitivity consideration
High
HLA-B*5701 risk is identified before therapy
Genetic testing is used to identify people at risk
High
Fever, rash, or systemic symptoms occur during treatment
These features fit an immune reaction more than a congenital hand finding
Moderate
Choose 3 4 Metacarpal Synostosis C5558402 when
Hand difference is noticed at birth
Congenital onset matches metacarpal synostosis
High
Imaging shows fused third and fourth metacarpals
Structural fusion defines the finding
High
Concern is grip strength or hand appearance
Functional and cosmetic effects are musculoskeletal, not drug-related
Moderate
How key tests differ
| Test | Abacavir Hypersensitivity C5768819 | 3 4 Metacarpal Synostosis C5558402 | Interpretation |
|---|---|---|---|
| HLA-B*5701 testing | Used before abacavir to identify risk | Not relevant | A risk marker, not proof that a reaction has occurred |
| Hand radiograph | No expected metacarpal fusion | May show third-fourth metacarpal fusion | Supports a congenital structural finding when clinically correlated |
| Clinical drug review | Recent or current abacavir exposure | No drug association | Exposure history distinguishes a reaction from a birth anomaly |
Prognosis comparison
Abacavir Hypersensitivity C5768819
- Outcome
- May be serious, but outcome depends on recognition and stopping the drug; exact prognosis is not established here
- Factors
- Prompt recognition, drug discontinuation, and clinical severity
3 4 Metacarpal Synostosis C5558402
- Outcome
- Usually a stable mild congenital difference, though function varies
- Factors
- Degree of fusion, grip limitation, and associated hand findings
Time frame: Acute drug reaction versus lifelong congenital condition
These conditions are not alternatives for one another; clinician interpretation is essential
Complications comparison
| Complication | Presentation |
|---|---|
| Severe systemic reaction | Potentially serious and may worsen if abacavir continues Not expected Stop the drug and seek urgent care if suspected; clinician confirmation is required |
| Reduced grip | Not characteristic May occur, with severity varying Function should be assessed individually |
| Appearance-related concern | Rash may occur during a reaction Persistent hand-shape difference may occur These appearance changes have different causes and courses |
Patient education highlights
- HighDo not restart abacavir
A suspected hypersensitivity reaction needs urgent clinician advice; abacavir should not be restarted without specialist direction.
- MediumCongenital hand finding
Metacarpal synostosis is present from birth and is not contagious or caused by HIV medicine.
- MediumIndividual assessment
Hand function, pain, and appearance concerns should guide personalized musculoskeletal care.